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TABLE 1 Operative Mortality Associated With Septal Myectomy* at North American
Hypertrophic Cardiomyopathy Centers, 2000–2014
Institution
No. of
Myectomies Age (yrs) Male (%)
Operative
Deaths†
n %
Mayo Clinic, Rochester, Minnesota 1,411 51  14 55 4‡ 0.3
Cleveland Clinic, Cleveland, Ohio 1,470§ 55  14 55 6 0.4
Tufts Medical Center, Boston,
Massachusettsk
348 52  15 56 4 1.1
Toronto General, Ontario, Canada 306 49  13 62 2 0.6
Mount Sinai–St. Luke’s and
Roosevelt, New York, New York
160 53  14 48 1 0.6
Totals 3,695 54  14 55 17 0.4
*Does not include myectomy associated with valve replacement, coronary artery bypass grafting, or resection of
a subaortic membrane. †Within 30 days of the myectomy. ‡Includes 2 patients with prior alcohol septal ablation;
with these 2 patients considered nonpure myectomies, the Mayo mortality rate would be only 0.15%. §Includes
19% of patients with mitral valve repair. kNewest myectomy center with operations performed over only 11 years
with ﬁrst procedure in 2004, whereas data for the other centers encompass 15 years.
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1308surgical myectomy should be considered a special-
ized operation best performed in high-volume HCM
institutions. Promotion of dedicated HCM centers (1)
is a strategy that will undoubtedly increase the
number of surgeons with myectomy experience and
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Gradient Predicts
Outcome in Patients With
Heart Failure and Preserved
Ejection FractionApproximately 50% of patients presenting with clin-
ical signs of heart failure are diagnosed with heart
failure with preserved ejection fraction (HFpEF) (1).
Pulmonary hypertension (PH) is a common feature of
HFpEF and predicts poor outcome. According to the
diastolic pressure gradient (DPG), deﬁned as diastolic
pulmonary arterial pressure (PAP) minus pulmonary
artery wedge pressure, PH-HFpEF can be classiﬁed
into passive PH (DPG <7 mm Hg) and mixed PH
(DPG $7 mm Hg). The main mechanism underlying
passive PH is simple backward transmission of
elevated left-sided ﬁlling pressures with a passive
increase in pulmonary vascular pressures (2). In
patients with mixed PH, a superimposed active
component caused by pulmonary arterial vasocon-
striction and/or vascular remodeling of the small
pulmonary arteries can lead to a further increase in
PAP (2). In the present single-center study, the prev-
alence and prognostic signiﬁcance of DPG elevation
were investigated in a well-deﬁned pure HFpEF
population.
Between 2010 and 2014, a total of 174 patients with
HFpEF (mean age 71  8 years; 64.9% female), diag-
nosed according to current guidelines (3), were pro-
spectively enrolled in a dedicated registry. PH-HFpEF
was conﬁrmed if pulmonary artery wedge pressure
was >12 mm Hg and mean PAP was $25 mm Hg as
measured by right heart catheterization. The primary
study endpoint was hospitalization for heart failure
or cardiac death.
The study cohort consisted of 26 HFpEF (14.9%)
patients without PH and 148 (85.1%) patients with
TABLE 1 Hemodynamic Predictors of Outcome in Patients With PH Due to Heart Failure With Preserved Ejection Fraction
Patients With
Passive PH
(n ¼ 126)
Patients With
Mixed PH
(n ¼ 22)
Univariable Multivariable
HR (95% CI) p Value HR (95% CI) p Value*
Directly measured parameters
Systolic pulmonary arterial pressure, mm Hg 54.9  14.4 65.4  22.3 1.023 (1.009–1.037) 0.001 1.055 (1.012–1.100) 0.012
Diastolic pulmonary arterial pressure, mm Hg 22.6  5.2 31.9  8.7 1.054 (1.017–1.093) 0.004
Mean pulmonary arterial pressure, mm Hg 35.2  7.7 42.9  12.3 1.037 (1.010–1.065) 0.006
Mean right atrial pressure, mm Hg 13.6  5.6 14.6  4.6 1.059 (1.010–1.110) 0.017
Pulmonary artery wedge pressure, mm Hg 21.3  4.8 20.2  5.9 1.037 (0.986–1.090) 0.157
Cardiac output, l/min 5.3  1.3 5.3  1.7 0.984 (0.807–1.200) 0.871
Calculated parameters
Diastolic pressure gradient, mm Hg 1.3  3.0 11.8  3.9 1.078 (1.018–1.141) 0.010 1.057 (1.017–1.097) 0.004
Transpulmonary pressure gradient, mm Hg† 13.9  5.0 22.7  7.5 1.058 (1.018–1.100) 0.004
Pulmonary vascular resistance,
dynes$s$cm5
221.0  93.3 377.9  185.9 1.003 (1.003–1.005) 0.006
Pulmonary pulse pressure, mm Hg 32.4  11.8 33.4  16.1 1.026 (1.007–1.044) 0.006 1.163 (1.048–1.291) 0.004
Pulmonary arterial compliance, ml/mm Hg‡ 2.6  1.1 2.7  1.7 0.850 (0.669–1.081) 0.186
Values are mean  SD unless otherwise indicated. Bold indicates signiﬁcance. *The multivariable analysis was conducted separately for directly measured and for calculated
parameters. †Mean pulmonary arterial pressure minus pulmonary artery wedge pressure. ‡Ratio of stroke volume to pulmonary pulse pressure.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; PH ¼ pulmonary hypertension.
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1309post-capillary PH, of whom 126 (85.1%) had passive
PH and 22 (14.9%) had mixed PH. Groups were com-
parable with respect to sex and age. A total of 22 pa-
tients (12.6%) had sleep apnea; 4 of these patients
(18.2%) were in the high DPG group. The overall
prevalence of chronic obstructive pulmonary disease
(COPD) in our patient population was 33%. Patients
with mixed PH had a signiﬁcantly higher prevalence
of COPD (50.0% vs. 30.2%; p ¼ 0.034) with a lower
capillary partial pressure of oxygen (63.4  9.7 mm Hg
vs. 73.3  11.6 mm Hg; p ¼ 0.001) and shorter 6-min
walk distances (253.5  128.6 m vs. 312.5  114.0 m;
p ¼ 0.034); N-terminal pro–B-type natriuretic peptide
levels (median: 1,895 pg/ml [interquartile range: 609
to 4,109 pg/ml] vs. 1,224 pg/ml [interquartile range:
552 to 1,993 pg/ml]; p ¼ 0.084) were not signiﬁcantly
different compared with patients who had isolated
passive PH. They presented with larger right ventri-
cles (42.1  8.9 mm vs. 37.6  6.6 mm; p ¼ 0.010),
larger pulmonary artery diameters (24.7  6.8 mm vs.
21.3  4.4 mm; p ¼ 0.041), and higher pulmonary
vascular resistance (377.9  185.9 dynes$s$cm5 vs.
221.0  93.3 dynes$s$cm5; p < 0.001). During a me-
dian follow-up time of 25.2 months, 55 patients
(31.6%) reached the composite endpoint. Elevated
DPG was independently associated with adverse
outcome (Table 1). The worst event-free survival was
observed in the group of patients with mixed PH
(log-rank test: non-PH vs. passive PH, p ¼ 0.003;
passive PH vs. mixed PH, p ¼ 0.015). Following the
hypothesis that advanced disease states as reﬂected
by marked enlargement of mean left atrial size withunderlying hemodynamic alterations downstream of
DPG or presence of atrial ﬁbrillation could trigger DPG
elevations, we performed univariable and multivari-
able regression analyses with respective parameters.
No association was found between DPG and down-
stream chamber sizes (left atrial diameter, odds ratio
[OR]: 1.022; 95% conﬁdence interval [CI]: 0.969 to
1.079; p ¼ 0.422; left ventricular diameter, OR: 0.960;
95% CI: 0.880 to 1.047; p ¼ 0.358), respective ﬁlling
pressures (pulmonary artery wedge pressure, OR:
0.951; 95% CI: 0.861 to 1.050; p ¼ 0.320), or atrial
ﬁbrillation (OR: 1.719; 95% CI: 0.630 to 4.695;
p ¼ 0.290). Of the lung function parameters tested,
only partial pressure of oxygen (OR: 0.923; 95% CI:
0.875 to 0.973; p ¼ 0.003) was the most signiﬁcant
predictor of DPG.
A causative role of hypoxemia in the evolution of
PH in COPD patients has been previously suggested
based on the observation that acute exposure to
low oxygen levels was followed by an increase in
diastolic pulmonary pressure, with no concomitant
increase in pulmonary artery wedge pressure or
pulmonary blood volume (4). Our ﬁndings are in line
with these observations, thereby explaining the high
prevalence of COPD in the high DPG group and sug-
gest a dual hit theory, in which HFpEF in combina-
tion with chronic pulmonary disease or HFpEF as a
consequence of pulmonary disease may primarily
trigger pulmonary vascular remodeling. From a cur-
rent perspective, a potential role for oxygen sup-
plementation at a low threshold and/or speciﬁc
vasodilators currently licensed for the treatment of
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1310precapillary PH remains to be elucidated in dedi-
cated clinical trials, speciﬁcally in patients with
high DPG.Caroline Zotter-Tufaro, MSc
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Warfarin in Dialysis
Patients With
Atrial FibrillationPatients with atrial ﬁbrillation (AF) and end-stage
chronic kidney disease (CKD) receiving dialysis are
at higher risk of stroke (1). Warfarin has been shown
to reduce the frequency of strokes by 64.0% in
patients with AF; however, its use in dialysis patients
has not received consensus owing to the lack of
randomized controlled trial data and associated
increased bleeding risk.
In a recently published paper in the Journal, Bonde
et al. (2) demonstrated that warfarin was associatedwith a reduction in all-cause mortality in high-risk
(CHA2DS2-VASc $2) dialysis patients in a large popu-
lation with AF in Denmark, with the majority (72.0%)
of these 1,728 patients receiving hemodialysis.
Like many of the published cohorts, the majority of
these patients with CKD did not receive warfarin
treatment despite having higher stroke risk, probably
due to the concomitant higher bleeding risk. Of note,
fewer than one-fourth of these dialysis patients
(22.9%) were receiving warfarin. In contrast to this
study, another recently published study (3) suggested
otherwise—that warfarin use was not associated with
reduction in stroke risk but was associated with a
44.0% increase in bleeding events, resulting in an
absence of net clinical beneﬁt in patients with AF
undergoing dialysis. Despite such contrasting results
in these 2 large cohorts, the latter did not differen-
tiate between hemodialysis and peritoneal dialysis
patients, who might have differences in baseline
patient characteristics and stroke and bleeding risks.
One of the merits of the latter study was a higher
proportion (46.0%) of dialysis patients prescribed
warfarin. Although the net clinical beneﬁt of warfarin
is always a balance between stroke and bleeding
risk, our recent ﬁnding (4) using a hospital-based
cohort with 9,810 patients with AF with all patients
with end-stage CKD (2.76%) on peritoneal dialysis
showed a similar beneﬁt of warfarin as the Denmark
cohort. In particular, among 271 patients with end-
stage CKD, all received peritoneal dialysis, with 67
patients (24.6%) on warfarin, and no ischemic or
hemorrhagic stroke event was observed during a
mean follow-up of 3.19 years. Although the number of
patients with end-stage CKD was much smaller
compared with the aforementioned cohorts, warfarin
was demonstrated to achieve a net clinical beneﬁt of
stroke reduction. Of note, the mean CHA2DS2-VASc
and HAS-BLED scores from our cohort did not differ
from those of the 2 cohorts (2.97  2.01 and 2.56 
0.97, respectively). Whether peritoneal dialysis pa-
tients might beneﬁt differently from anticoagulation
is still debatable; in particular, the quality of anti-
coagulation, as reﬂected by the time in therapeutic
range, is largely unknown from most of these studies,
which might impact both the ischemic and hemor-
rhagic stroke risk.
Owing to the heterogeneous nature of patients
with end-stage CKD and the existing conﬂicting
results from the cohort studies, a large-scale ran-
domized controlled trial including hemodialysis and
peritoneal dialysis patients from different ethnic
origins might help to determine the optimal anti-
coagulation regimen in patients with end-stage CKD
on different modalities of renal replacement therapy.
